Instacart downgraded as competition tightening grip on online grocery
Monday’s market has seen significant movements among a range of stocks, with some experiencing notable gains while others faced declines. Mega-cap stocks like Alibaba (BABA) and Palantir Technologies Inc (PLTR) have made impressive strides, while others in the large-cap category, such as Summit Therapeutics PLC (SMMT), have seen substantial drops. Below, we delve into some of the day’s biggest stock movers across various market cap categories.
Mega-Cap Movers:
- Alibaba (BABA): +3.23%
- Palantir Technologies Inc (PLTR): +2.36%
- Avago Technologies (AVGO): +2.76%
- Oracle Corp (ORCL): +2.49%
- Pepsico (PEP): -3.75%
- Metropcs Communications (TMUS): -2.99%
Large-Cap Stock Movers:
- EchoStar Corp (SATS); EchoStar to sell spectrum licenses to SpaceX for $17 billion: +17.3%
- Astera Labs (ALAB): +14.12%
- Robinhood Markets (HOOD): +13.91%
- Applovin (APP): +10.41%
- Coupang LLC (CPNG): +8.84%
- Summit Therapeutics PLC (SMMT): -25.69%
- Biontech Se (BNTX): -8.66%
- New Providence Acquisition Corp N (ASTS): -5.78%
Mid-Cap Stock Movers:
- Kensington Capital Acquisition (QS): +19.83%
- Globalstar Inc (GSAT): +18.7%
- Centessa Pharmaceuticals ADR (CNTA): +15.0%
- Hecla Mining Comp (HL): +12.36%
- Scorpio Tankers Inc (STNG); BofA Securities upgrades Scorpio Tankers stock to Buy on strong product tanker rates: +10.43%
- Iridium Communications (IRDM): -12.36%
Small-Cap Stock Movers:
- Rapport Therapeutics (RAPP); Rapport’s epilepsy drug shows 78% seizure reduction in phase 2 trial: +123.02%
- Planet Labs PBC (PL): +40.12%
- Loandepot Inc (LDI): +28.37%
- Kindly MD (NAKA): +21.32%
- Magenta Therapeutics (DNTH); Dianthus to discuss phase 2 myasthenia gravis trial results Monday: +19.7%
- New Fortress Energy LLC (NFE): -40.81%
- Scage Future ADR (SCAG): -22.18%
- nFusz (TONX); TON Strategy Company reports $11.90 per share treasury value: -18.35%
For real-time, market-moving news, join Investing Pro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.